Lisa Astor

Adding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.

A regimen combining the PARP inhibitor and the androgen receptor pathway inhibitor plus prednisone showed promise in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

The HIF-2α inhibitor continued to induce strong responses in patients with Von-Hippel Lindau (VHL)–associated renal cell carcinoma and other VHL-associated neoplasms.

The antibody-drug conjugate was previously granted an accelerated approval by the FDA in this setting based on results from the phase 2 EV-201 trial.

Phase 1 data suggest the anti–PD-1 immune checkpoint inhibitor is safe and tolerable in the neoadjuvant setting for patients with nonmetastatic high-risk clear cell renal cell carcinoma.